Amicus Therapeutics, Inc. (LON:0HF9)
5.86
+0.01 (0.24%)
At close: Jun 18, 2025
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $125.25M USD in the quarter ending March 31, 2025, with 13.45% growth. This brings the company's revenue in the last twelve months to $543.14M, up 28.25% year-over-year. In the year 2024, Amicus Therapeutics had annual revenue of $528.30M with 32.29% growth.
Revenue (ttm)
$543.14M
Revenue Growth
+28.25%
P/S Ratio
3.12
Revenue / Employee
$1.09M
Employees
499
Market Cap
1.31B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 528.30M | 128.94M | 32.29% |
Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Indivior | 905.57M |
Amicus Therapeutics News
- 4 days ago - The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy - GlobeNewsWire
- 7 days ago - In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid - GlobeNewsWire
- 8 days ago - In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime - GlobeNewsWire
- 8 days ago - Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma - Seeking Alpha
- 17 days ago - New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve - GlobeNewsWire
- 21 days ago - Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - GlobeNewsWire
- 6 weeks ago - Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference - GlobeNewsWire
- 7 weeks ago - Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript - Seeking Alpha